A Phase 1 interventional study of NG004 in Acute Spinal Cord Injury (SCI), Spinal Cord Diseases and Central Nervous System Diseases, sponsored by NovaGo Therapeutics AG. Active, not recruiting at 6 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by NovaGo Therapeutics AG · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Spinal Cord Injuries with a site in Germany — 3 open to participants now, 6 under way, none of them phase 3. Spinal Cord Injuries · Germany.
Among the 22 studies in Spinal Cord Injuries with a site in Germany, this one is the 10th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2024, is one of 4 in phase 1, and was the 19th registered.
2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.
Browse Spinal Cord Injuries studies →3 of the 22 studies in Spinal Cord Injuries with a site in Germany are open now. Recruiting first, the newest first:
NovaGo Therapeutics AG · Sites in Germany, Switzerland
Ages 18–75
AO Foundation, AO Spine · Sites in Germany, United States, Australia and 5 more countries
Ages 19+
St George's, University of London · Sites in Germany, Austria, Belgium and 9 more countries
Ages 16+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 24 across 1,639 interventional studies indexed under Spinal Cord Injuries.
Median enrollment 38 across the 14 interventional studies, 185 across the 8 observational. Of the 15 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 22 have an industry lead sponsor. The 10 most frequent:
NovaGo Therapeutics AG is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
NovaGo Therapeutics AG has 2 studies filed under Spinal Cord Injuries — fewer than ten, so there is no comparison to draw.
1 of the studies in Spinal Cord Injuries with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06817577NovaGo Therapeutics AGNG004 in Spinal Cord Injury Patients | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Spinal Cord Injuries with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is the FIH, multicenter, open-label, sequential, multiple ascending dose trial of NG004 in patients with acute incomplete cervical SCI. The trial will evaluate the safety, tolerability, and PK of 4 dose regimens of NG004, and will evaluate the maximum tolerated dose of NG004. The trial consists of Part A (the dose escalation) and Part B (the PK-confirmation at 2 dose levels from Part A).
2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.
This study's planned enrollment of 20 is below the median of 24 across 1,639 interventional studies indexed under Spinal Cord Injuries.
Browse Spinal Cord Injuries studies →NovaGo Therapeutics AG is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Compared within Spinal Cord Injuries, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Spinal Cord Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: NG004
repeated intrathecal injections of NG004
Type, frequency, severity, and causal relationship of adverse events (AEs), serious AEs, and adverse drug reactions
Time frame: From treatment start up to 6 months
Maximum Plasma Concentration [Cmax] in serum
Time frame: After first and last intrathecal injection, measured at pre-dose and 1, 3, 6, 24, 48 hours post-dose.
Half-life in serum [T1/2]
Time frame: After last intrathecal injection up to 6 months
Effect on motor function as Change from Baseline in ISNCSCI upper extremities motor score (UEMS), according to the International Standards for the Neurological Classification of Spinal Cord Injury (ISNCSCI) protocol
The ISNCSCI bilateral Upper Extremity Motor Score (UEMS) is determined by examining the muscle function within each of the 5 myotomes encompassing arm and hand function on each side of the body. A score ranging from 0 to 5 can be given to each myotome tested resulting in a maximum score of 50. Higher values indicate better recovery.
Time frame: Baseline up to 6 months
Effect on daily life functioning according to change in Version III of the Spinal Cord Independence Measure (SCIM-III)
The SCIM III questionnaire self-care score assesses activities of daily living including feeding, bathing, dressing, and grooming. The self-care score ranges 0-20. The higher scores correspond to better ability to carry out the self-care activities.
Time frame: Baseline to 6 months
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Mar 2027, 27 months after the start.
Of 51 phase 1 interventional studies under Spinal Cord Injuries, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 27 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NovaGo Therapeutics AG